Searched for
TATVA CHINTAN SHARE
Q4 earnings roundup: Raymond Realty, MCX among 19 companies that delivered 100%+ growth in sales and PATA select group of 19 large-cap BSE-listed companies achieved triple-digit growth in both profit and revenue during Q4FY26, indicating stron...
Mukul Agrawal picks 1.28% stake in this underperforming stock, drives 14% surgeAccording to the latest shareholding data for the quarter ending June 2025, the prominent investor acquired 3 lakh shares of the company, a...
Buy Tatva Chintan Pharma Chem, target price Rs 2000: ICICI SecuritiesTatva Chintan Pharma Chem Ltd. key Products/Revenue Segments include Speciality Chemicals, Scrap and Export Incentives for the year ending ...
Tatva Chintan plunges 7% after 56% YoY fall in Q1 profitAfter the financial update, the scrip hit a day’s low of Rs 2161. At 11:05 am, it traded at Rs 2233.35 around 5.5 per cent below its previo...
Tatva Chintan Pharma sinks 10% as Q4 show disappointsEarlier this month, ICICI Securities said it has a buy call on Tatva Chintan Pharma Chem with a target price of Rs 3,000. Time period given...
Buy Tatva Chintan Pharma Chem, target price Rs 3000: ICICI SecuritiesTatva Chintan Pharma Chem Ltd., incorporated in the year 1996, is a Small Cap company (having a market cap of Rs 5184.96 Crore) operating i...
Buy Tatva Chintan Pharma Chem, target price Rs 3110: ICICI SecuritiesTatva Chintan Pharma Chem Ltd., incorporated in the year 1996, is a Small Cap company (having a market cap of Rs 5757.71 Crore) operating i...
Tatva Chintan Pharma shares tumble 9% post Dec quarter earningsThe Ebitda declined 6 per cent to Rs 23 crore compared with Rs 25 crore posted last year. The company’s margin contracted to 22 per cent in...
Buy Tatva Chintan Pharma Chem, target price Rs 2920: ICICI SecuritiesTatva Chintan Pharma Chem Ltd., incorporated in the year 1996, is a Small Cap company (having a market cap of Rs 5520.87 Crore) operating i...
Tatva Chinta Pharma surges 11% as investors welcome industrial land buy in GujaratThe step, seen as an indicator of growth prospects by investors, send the company’s scrip shooting up to a high of Rs 2,599.90 on the Natio...
Tatva Chintan Pharma jumps 17%, hits 52-week high on strong Q2 showThe company's revenue from operations during the second quarter of the financial year 2021-22 (Q2FY22) surged 105.8 per cent YoY to Rs 123....
Rolex Rings initial offer subscribed 130 timesThe `731-crore initial public offering of Rolex Rings, an automotive component company, was subscribed 130 times on Friday— the last day of...
Tatva Chintan surges over 100% on day 1Tatva Chintan's first-day pop is among the strongest listings that the market has seen of late. Recently, food delivery platform Zomato lis...
Will Tatva Chintan do a GR Infra on listing? Grey market says soThe grey market premium for the stock has surged to Rs 1,140-1,150 per share in the unofficial market, which can translate into 105-110 per...
Tatva Chintan IPO allotment: Check GMP and application statusThe basis of allotment for shares of Tatva Chintan is likely to be finalised by Monday, July 26. The shares of the company are expected to ...
Tatva Chintan Pharma’s IPO subscribed 180 timesThis is the second-best IPO so far this year in terms of investor demand. Earlier in March, the ₹596-crore IPO of MTAR Technologies was sub...
Tatva Chintan Pharma Chem IPO subscribed 15 times on Day 2Tatva Chintan Pharma Chem has already received bids worth Rs 149.99 crore from 22 anchor investors at the upper price band of Rs 1,083 per ...
Zomato IPO likely to sail through despite concernsExperts say profitability concerns, offer size may keep a lid on subscription numbers
Chemplast Sanmar, Tatva Chintan Pharma Chem get Sebi nod for IPOsChemplast Sanmar and Tatva Chintan Pharma Chem obtained Sebi's observations on July 2 and June 30 respectively, an update with Sebi showed ...
Tatva Chintan Pharma Chem files papers for Rs 450 cr IPOThe initial public offer (IPO) comprises fresh issuance of equity shares worth Rs 225 crore and an offer of sale to the tune of Rs 225 cror...